MiRABO Biotechnology raises $2.9M pre-Series A for its antibody drug AI
What's the deal? MiRABO BiotechnologyDealroom has a profile for this one. Try Dealroom →, an AI-based antibody drug development platform, has raised US$3.35M in an early VC round. Stonebridge VenturesDealroom has a profile for this one. Try Dealroom → led the round, with FuturePlayDealroom has a profile for this one. Try Dealroom → joining.
What does it do? The company uses its in-house AI engine, MiRAiQ, to shorten the drug development cycle from candidate discovery through process development to commercial production. Its three engines cover protein structure prediction, protein engineering and bioprocess modelling.
What it means. MiRABO is targeting the gap between contract manufacturers such as LonzaDealroom has a profile for this one. Try Dealroom → and WuXi BiologicsDealroom has a profile for this one. Try Dealroom →, and AI drug-discovery firms including Generate BiomedicinesDealroom has a profile for this one. Try Dealroom → and AbsciDealroom has a profile for this one. Try Dealroom →. It plans to combine subscription software and co-development contracts with a longer-term proprietary pipeline.
MiRABO is headquartered in Hong Kong and has an R&D centre in Shanghai. In January 2026, it signed a strategic agreement with CMP ScientificDealroom has a profile for this one. Try Dealroom →, and in March 2026 it began work with IMBiologicsDealroom has a profile for this one. Try Dealroom → on antibody pipelines.
Read more: Edaily
Image credit: Generated with Gemini
